Suppression of p53-mediated growth factor withdrawal-induced apoptosis in the myeloid compartment by hematopoietic cytokines: An overview of hematopoiesis and apoptosis with a presentation of thrombopoietin and the M07E cell line as a model system

Critical Reviews in Oncology/Hematology

Volumn 31, Issue 3, 1999, Pages 169-191

  Ritchie, Alec ^a,b   E Broxmeyer, Hal ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD34 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; FERRITIN; FIBRINOGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERFERON; INTERLEUKIN 3; MYC PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN DERIVATIVE; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE; STEEL FACTOR; THROMBOPOIETIN; TUMOR NECROSIS FACTOR;

ACUTE MEGAKARYOCYTIC LEUKEMIA; APOPTOSIS; CELL CULTURE; CELL LINE; CULTURE MEDIUM; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032859258     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00018-9     Document Type: Article

References (377)

1. Broxmeyer H.E., Williams D.E. The production of myeloid blood cells and their regulation during health and disease. Crit Rev Oncol Hematol. 8:1988;173-226.
2. Bekkum D.Wv., Noord M.Jv., Maat B. et al. Attempts at identification of hemopoietic stem cell in mouse. Blood. 38:1971;547-558.
3. Lemischka I.R. The haematopoietic stem cell and its clonal progeny: mechanisms regulating the hierarchy of primitive haematopoietic cells. Cancer Surv. 15:1992;3-18.
4. Nakahata T., Ogawa M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc Natl Acad Sci USA. 79:1982;3843-3847.
5. Broxmeyer H.E. Self-renewal and migration of stem cells during embryonic and fetal hematopoiesis: important, but poorly understood events. Blood Cells. 17:1991;282-286.
6. Mintz B., Anthony K., Litwin S. Monoclonal derivation of mouse myeloid and lymphoid lineages from totipotent hematopoietic stem cells experimentally engrafted in fetal hosts. Proc Natl Acad Sci USA. 81:1984;7835-7839.
7. Okuyama R., Koguma M., Yanai N. et al. Bone marrow stromal cells induce myeloid and lymphoid development of the sorted hematopoietic stem cells in vitro. Blood. 86:1995;2590-2597.
8. Ford C.E., Micklem H.S., Ogden D.A. Evidence for the existence of a lymphoid stem cell. Lancet. 1:1968;621-622.
9. Broxmeyer HE. Hematopoietic stem cells. In: Trubowitz S, Davis E, editors. The Human Bone Marrow. Boca Raton, FL: CRC Press 1981:77-123.
10. McCulloch E.A., Till T.E. The radiation sensitivity of normal bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res. 13:1960;115.
11. Till J.E., McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 14:1961;213.
12. Storb U., Kruisbeek A.M. Lymphocyte development. Curr Opin Immunol. 8:1996;155-159.
13. Lee W.M. Cellular and humoral immunity in viral hepatitis. Am J Clin Pathol. 65:1976;866-869.
14. Brandtzaeg P. The human intestinal immune system: basic cellular and humoral mechanisms. Baillieres Clin Rheumatol. 10:1996;1-24.
15. Nicola N.A., Johnson G.R. The production of committed hemopoietic colony-forming cells from multipotential precursor cells in vitro. Blood. 60:1982;1019-1029.
16. Metcalf D., Johnson G.R., Mandel T.E. Colony formation in agar by multipotential hemopoietic cells. J Cell Physiol. 98:1979;401-420.
17. Iscove N.N., Roitsch C.A., Williams N. et al. Molecules stimulating early red cell, granulocyte, macrophage, and megakaryocyte precursors in culture: similarity in size, hydrophobicity, and charge. J Cell Physiol Suppl. 1:1982;65-78.
18. Carow C.E., Hangoc G., Broxmeyer H.E. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood. 81:1993;942-949.
19. Traycoff C.M., Abboud M.R., Laver J. et al. Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential. Exp Hematol. 22:1994;1264-1272.
20. Srour E.F., Brandt J.E., Briddell R.A. et al. Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood. 81:1993;661-669.
21. Verfaillie C.M. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood. 82:1993;2045-2053.
22. Leary A.G. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest. 74:1984;2193-2199.
23. Lu L., Xiao M., Shen R.N. et al. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood. 81:1993;41-48.
24. Cline M.J., Golde D.W. Production of colony-stimulating activity by human lymphocytes. Nature. 248:1974;703-704.
25. Broxmeyer H.E. Biomolecule-cell interactions and the regulation of myelopoiesis. Int J Cell Clon. 4:1986;378.
26. Dexter T.M., Fairbairn L.J. The molecular control of hematopoiesis. Anticancer Drugs. 4(Suppl 1):1993;5-12.
27. Dexter T.M., Simmons P., Purnell R.A. et al. The regulation of hemopoietic cell development by the stromal cell environment and diffusible regulatory molecules. Prog Clin Biol Res. 148:1984;13-33.
28. Clark B.R., Gallagher J.T., Dexter T.M. Cell adhesion in the stromal regulation of haemopoiesis. Baillieres Clin Haematol. 5:1992;619-652.
29. Burroughs J., Gupta P., Blazar B.R. et al. Diffusible factors from the murine cell line M2-10B4 support human in vitro hematopoiesis. Exp Hematol. 22:1994;1095-1101.
30. Dexter T.M. Haemopoiesis in long-term bone marrow cultures. A review. Acta Haematol. 62:1979;299-305.
31. Dexter T.M., Spooncer E., Simmons P. et al. Long-term marrow culture: an overview of techniques and experience. Kroc Found Ser. 18:1984;57-96.
32. Gordon M.Y., Clarke D., Atkinson J. et al. Hemopoietic progenitor cell binding to the stromal microenvironment in vitro. Exp Hematol. 18:1990;837-842.
33. Verfaillie C., Blakolmer K., McGlave P. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med. 172:1990;509-512.
34. Papayannopoulou T., Craddock C. Homing and trafficking of hemopoietic progenitor cells. Acta Haematol. 97:1997;97-104.
35. Buck C.A., Horwitz A.F. Cell surface receptors for extracellular matrix molecules. Annu Rev Cell Biol. 3:1987;179-205.
36. Labat-Robert J., Bihari-Varga M., Robert L. Extracellular matrix. FEBS Lett. 268:1990;386-393.
37. Shattil S.J., Ginsberg M.H. Perspectives series: cell adhesion in vascular biology. Integrin signaling in vascular biology. J Clin Invest. 100:1997;1-5.
38. Shattil S.J., Gao J., Kashiwagi H. Not just another pretty face: regulation of platelet function at the cytoplasmic face of integrin alpha IIb beta 3. Thromb Haemost. 78:1997;220-225.
39. Juliano R. Cooperation between soluble factors and integrin-mediated cell anchorage in the control of cell growth and differentiation. Bioessays. 18:1996;911-917.
40. Loftus J.C., Liddington R.C. Cell adhesion in vascular biology. New insights into integrin-ligand interaction. J Clin Invest. 99:1997;2302-2306.
41. Borge O.J., Ramsfjell V., Cui L. et al. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood. 90:1997;2282-2292.
42. Ku H., Yonemura Y., Kaushansky K. et al. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood. 87:1996;4544-4551.
43. Broxmeyer H.E., Cooper S., Lu L. et al. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood. 77:1991;2142-2149.
44. Williams D.E., Fletcher F.A., Lyman S.D. et al. Cytokine regulation of hematopoietic stem cells. Semin Immunol. 3:1991;391-396.
45. Veiby O.P., Jacobsen F.W., Cui L. et al. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol. 157:1996;2953-2960.
46. Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 248:1990;378-381.
47. Yonish-Rouach E., Resnitzky D., Lotem J. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
48. Ritchie A., Vadhan-Raj S., Broxmeyer H.E. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells. 14:1996;330-336.
49. McKenna S.L., Cotter T.G. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res. 71:1997;121-164.
50. Taga T., Kishimoto T. Cytokine receptors and signal transduction. Faseb J. 6:1992;3387-3396.
51. Ihle J.N., Witthuhn B., Tang B. et al. Cytokine receptors and signal transduction. Baillieres Clin Haematol. 7:1994;17-48.
52. Wells J.A., de Vos A.M. Hematopoietic receptor complexes. Annu Rev Biochem. 65:1996;609-634.
53. Karin M. Signal transduction and gene control. Curr Opin Cell Biol. 3:1991;467-473.
54. Frederickson R.M., Sonenberg N. Signal transduction and regulation of translation initiation. Semin Cell Biol. 3:1992;107-115.
55. Pawson T. Tyrosine kinases and their interactions with signalling proteins. Curr Opin Genet Dev. 2:1992;4-12.
56. Schlessinger J. Cellular signaling by receptor tyrosine kinases. Harvey Lect. 89:1993;105-123.
57. Ihle J.N., Witthuhn B.A., Quelle F.W. et al. Protein tyrosine phosphorylation in the regulation of hematopoiesis by receptors of the cytokine-receptor superfamily. Blood Cells. 20:1994;65-80. discussion 80-62.
58. Marshall M.S. The effector interactions of p21ras. Trends Biochem Sci. 18:1993;250-254.
59. Marshall M.S. Ras target proteins in eukaryotic cells. Faseb J. 9:1995;1311-1318.
60. Osborne N.N., Tobin A.B., Ghazi H. Role of inositol trisphosphate as a second messenger in signal transduction processes: an essay. Neurochem Res. 13:1988;177-191.
61. Penner R., Neher E. The role of calcium in stimulus-secretion coupling in excitable and non-excitable cells. J Exp Biol. 139:1988;329-345.
62. Hawes B.E., Conn P.M. Assessment of the role of G proteins and inositol phosphate production in the action of gonadotropin-releasing hormone. Clin Chem. 39:1993;325-332.
63. de Chaffoy de Courcelles D. The use of diacylglycerol kinase inhibitors for elucidating the roles of protein kinase C. Adv Second Messenger Phosphoprotein Res. 24:1990;491-496.
64. Nairn A.C., Picciotto M.R. Calcium/calmodulin-dependent protein kinases. Semin Cancer Biol. 5:1994;295-303.
65. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem. 58:1989;453-508.
66. Blenis J., Resh M.D. Subcellular localization specified by protein acylation and phosphorylation. Curr Opin Cell Biol. 5:1993;984-989.
67. Pawson T. SH2 and SH3 domains in signal transduction. Adv Cancer Res. 64:1994;87-110.
68. Schlessinger J. SH2/SH3 signaling proteins. Curr Opin Genet Dev. 4:1994;25-30.
69. Winston L.A., Hunter T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem. 270:1995;30837-30840.
70. Johnson G.L., Vaillancourt R.R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol. 6:1994;230-238.
71. Hardie D.G. Roles of protein kinases and phosphatases in signal transduction. Symp Soc Exp Biol. 44:1990;241-255.
72. Land H., Parada L.F., Weinberg R.A. Cellular oncogenes and multistep carcinogenesis. Science. 222:1983;771-778.
73. Weinberg R.A. Finding the anti-oncogene. Sci Am. 259:1988;44-51.
74. Varmus H.E. Oncogenes and transcriptional control. Science. 238:1987;1337-1339.
75. Williams G.T., Smith C.A., Spooncer E. et al. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 343:1990;76-79.
76. Crompton T. IL3-dependent cells die by apoptosis on removal of their growth factor. Growth Factors. 4:1991;109-116.
77. Williams D.E., Straneva J.E., Cooper S. et al. Interactions between purified murine colony-stimulating factors (natural CSF-1, recombinant GM-CSF, and recombinant IL-3) on the in vitro proliferation of purified murine granulocyte-macrophage progenitor cells. Exp Hematol. 15:1987;1007-1012.
78. Broxmeyer H.E., Williams D.E., Cooper S. et al. Recombinant human granulocyte-colony stimulating factor and recombinant human macrophage-colony stimulating factor synergize in vivo to enhance proliferation of granulocyt-macrophage, erythroid, and multipotential progenitor cells in mice. J Cell Biochem. 38:1988;127-136.
79. Sasaki H., Hirabayashi Y., Inoue T. et al. Promotion of survival and proliferation by interleukin 3, kit-ligand and erythropoietin on early and late appearing spleen colony forming units in culture. Stem Cells (Dayt). 11:1993;555-561.
80. Takahira H., Lyman S.D., Broxmeyer H.E. Flt3 ligand prolongs survival of CD34++ + human umbilical cord blood myeloid progenitors in serum-depleted culture medium. Ann Hematol. 72:1996;131-135.
81. Bodine D.M., Karlsson S., Nienhuis A.W. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci U S A. 86:1989;8897-8901.
82. Borge O.J., Ramsfjell V., Veiby O.P. et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood. 88:1996;2859-2870.
83. Begley C.G., Lopez A.F., Nicola N.A. et al. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood. 68:1986;162-166.
84. Kelley L.L., Koury M.J., Bondurant M.C. et al. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 82:1993;2340-2352.
85. Ritchie A., Gotoh A., Gaddy J. et al. Thrombopoietin upregulates the promoter conformation of p53 in a proliferation-independent manner coincident with a decreased expression of Bax: potential mechanisms for survival enhancing effects. Blood. 90:1997;4394-4402.
86. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:1972;239-257.
87. Wyllie A.H. Apoptosis: cell death in tissue regulation. J Pathol. 153:1987;313-316.
88. Cotter T.G., Lennon S.V., Glynn J.M. et al. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res. 52:1992;997-1005.
89. Fadok V.A., Voelker D.R., Campbell P.A. et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 148:1992;2207-2216.
90. Martin S.J., Reutelingsperger C.P., McGahon A.J. et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 182:1995;1545-1556.
91. Columbano A. Cell death: current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo. J Cell Biochem. 58:1995;181-190.
92. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 146:1995;3-15.
93. Filipski J., Leblanc J., Youdale T. et al. Periodicity of DNA folding in higher order chromatin structures. EMBO J. 9:1990;1319-1327.
94. Arends M.J., Wyllie A.H. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol. 32:1991;223-254.
95. Anzai N., Kawabata H., Hirama T. et al. Types of nuclear endonuclease activity capable of inducing internucleosomal DNA fragmentation are completely different between human CD34+ cells and their granulocytic descendants. Blood. 86:1995;917-923.
96. Li H., Bergeron L., Cryns V. et al. Activation of caspase-2 in apoptosis. J Biol Chem. 272:1997;21010-21017.
97. Reid S., Cross R., Snow E.C. Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis. J Immunol Methods. 192:1996;43-54.
98. Koopman G., Reutelingsperger C.P., Kuijten G.A. et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415-1420.
99. Nicholson D.W., Ali A., Thornberry N.A. et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis [see comments]. Nature. 376:1995;37-43.
100. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1993;1945-1951.
101. Li X., Darzynkiewicz Z. Labeling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif. 28:1995;572-579.
102. Cowling G.J., Dexter T.M. Apoptosis in the haemopoietic system. Philos Trans R Soc Lond B Biol Sci. 345:1994;257-263.
103. Lotem J., Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia. 10:1996;925-931.
104. Murohashi I., Yoshida K., Handa A. et al. Differential regulation by hematopoietic growth factors of apoptosis and mitosis in acute myeloblastic leukemia cells. Exp Hematol. 25:1997;1042-1050.
105. DiGiuseppe J.A., Kastan M.B. Apoptosis in haematological malignancies. J Clin Pathol. 50:1997;361-364.
106. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 82:1993;15-21.
107. Mountz J.D., Zhou T., Su X. et al. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol. 80:1996;S2-14.
108. Ridet A., Guillouf C., Duchaud E. et al. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Cancer Res. 57:1997;1722-1730.
109. Webb S.J., Harrison D.J., Wyllie A.H. Apoptosis: an overview of the process and its relevance in disease. Adv Pharmacol. 41:1997;1-34.
110. Antoku K., Liu Z., Johnson D.E. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia. 11:1997;1665-1672.
111. Bergman P.J., Harris D. Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract. 27:1997;47-57.
112. Schulze-Osthoff K., Krammer P.H., Dröge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 13:1994;4587-4596.
113. Um H.D., Orenstein J.M., Wahl S.M. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol. 156:1996;3469-3477.
114. Chinnaiyan A.M., O'Rourke K., Tewari M. et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505-512.
115. Hofmann K., Tschopp J. The death domain motif found in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance. FEBS Lett. 371:1995;321-323.
116. Schimke R.T., Kung A., Sherwood S.S. et al. Life, death and genomic change in perturbed cell cycles. Philos Trans R Soc Lond B Biol Sci. 345:1994;311-317.
117. Yoshida M., Usui T., Tsujimura K. et al. Biochemical differences between staurosporine-induced apoptosis and premature mitosis. Exp Cell Res. 232:1997;225-239.
118. Chen X., Ko L.J., Jayaraman L. et al. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:1996;2438-2451.
119. Yuan Z.M., Huang Y., Ishiko T. et al. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA. 94:1997;1437-1440.
120. Williams G.T. Programmed cell death: apoptosis and oncogenesis. Cell. 65:1991;1097-1098.
121. Lee J.M., Abrahamson J.L., Bernstein A. DNA damage, oncogenesis and the p53 tumour-suppressor gene. Mutat Res. 307:1994;573-581.
122. Tewari M., Yu M., Ross B. et al. AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res. 57:1997;4063-4069.
123. Kummer J.L., Rao P.K., Heidenreich K.A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 272:1997;20490-20494.
124. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:1994;619-626.
125. Frisch S.M., Vuori K., Ruoslahti E. et al. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 134:1996;793-799.
126. Frisch S.M., Vuori K., Kelaita D. et al. A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J Cell Biol. 135:1996;1377-1382.
127. Bates R.C., Lincz L.F., Burns G.F. Involvement of integrins in cell survival. Cancer Metastasis Rev. 14:1995;191-203.
128. Zhang Z., Vuori K., Reed J.C. et al. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA. 92:1995;6161-6165.
129. Scott G., Cassidy L., Busacco A. Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol. 108:1997;147-153.
130. Mangan D.F., Wahl S.M. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol. 147:1991;3408-3412.
131. Kuter D.J., Rosenberg R.D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 85:1995;2720-2730.
132. Nagata Y., Shozaki Y., Nagahisa H. et al. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost. 77:1997;808-814.
133. Raff M.C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
134. Broxmeyer HE. Negative regulators of hematopoiesis. In: Wright D, Greenberger J, editors. Long term bone marrow culture: present experience and future possibilities. New York: Allan R. Liss, 1984;18:383-97.
135. Rollins B.J. Chemokines. Blood. 90:1997;909-928.
136. Kim C.H., Broxmeyer H.E. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: Stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 91:1998;100-110.
137. Broxmeyer H.E., Cooper S., Maione T. et al. Myeloprotective effects of the chemokines interleukin-8 and platelet factor 4 in a mouse model of cytosine arabinoside (ARA-C) chemotherapy. Exp Hematol. 23:1995;900-907.
138. Graham G.J., Wright E.G., Hewick R. et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 344:1990;442-444.
139. Broxmeyer H.E., Cooper S., Hague N. et al. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor dependent cell line and in vivo in mice. Ann Hematol. 71:1995;235-246.
140. Jenkins J.R., Rudge K., Currie G.A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature. 312:1984;651-654.
141. Abrahamson J.L., Lee J.M., Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol. 15:1995;6953-6960.
142. Blandino G., Scardigli R., Rizzo M.G. et al. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene. 10:1995;731-737.
143. Canman C.E., Gilmer T.M., Coutts S.B. et al. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9:1995;600-611.
144. Deng C., Zhang P., Harper J.W. et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
145. Arrowsmith C.H., Morin P. New insights into p53 function from structural studies. Oncogene. 12:1996;1379-1385.
146. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
147. Xiong Y., Hannon G.J., Zhang H. et al. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
148. Kastan M.B., Zhan Q., el-Deiry W.S. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
149. Chin P.L., Momand J., Pfeifer G.P. In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation. Oncogene. 15:1997;87-99.
150. Oliner J.D., Pietenpol J.A., Thiagalingam S. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
151. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
152. Zhu Y.M., Bradbury D.A., Russell N.H. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer. 69:1994;468-472.
153. Lanza F., Bi S., Moretti S. et al. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. Br J Haematol. 90:1995;8-14.
154. Lotem J., Sachs L. A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci USA. 92:1995;9672-9676.
155. Soddu S., Blandino G., Scardigli R. et al. Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol. 16:1996;487-495.
156. Prisco M., Hongo A., Rizzo M.G. et al. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol. 17:1997;1084-1092.
157. Johnson P., Chung S., Benchimol S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol. 13:1993;1456-1463.
158. Lotem J., Sachs L. Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis. Proc Natl Acad Sci USA. 94:1997;9349-9353.
159. Lin Y., Benchimol S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Mol Cell Biol. 15:1995;6045-6054.
160. Lin Y., Benchimol S. p53-mediated cell cycle arrest and apoptosis. Leukemia. 11(Suppl 3):1997;324-326.
161. Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature. 310:1984;143-145.
162. Ullrich S.J., Mercer W.E., Appella E. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene. 7:1992;1635-1643.
163. Milner J., Gamble J. The SV40 large T-p53 complex: evidence for the presence of two immunologically distinct forms of p53. Virology. 147:1985;206-209.
164. Milner J., Cook A. The cellular tumour antigen p53: evidence for transformation-related, immunological variants of p53. Virology. 154:1986;21-30.
165. Gamble J., Milner J. Evidence that immunological variants of p53 represent alternative protein conformations. Virology. 162:1988;452-458.
166. Cook A., Milner J. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer. 61:1990;548-552.
167. Milner J., Watson J.V. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene. 5:1990;1683-1690.
168. Milner J. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc R Soc Lond B Biol Sci. 245:1991;139-145.
169. Gannon J.V., Greaves R., Iggo R. et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
170. Rivas C.I., Wisniewski D., Strife A. et al. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood. 79:1992;1982-1986.
171. Zambetti G.P., Levine A.J. A comparison of the biological activities of wild-type and mutant p53. Faseb J. 7:1993;855-865.
172. Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
173. Zerrahn J., Deppert W., Weidemann D. et al. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene. 7:1992;1371-1381.
174. Zhang W., Hu G., Estey E. et al. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene. 7:1992;1645-1647.
175. Zhang W., Deisseroth A.B. Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. Leuk Lymphoma. 14:1994;251-255.
176. Sabapathy K., Klemm M., Jaenisch R. et al. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J. 16:1997;6217-6229.
177. Milner J., Medcalf E.A. Temperature-dependent switching between 'wild-type' and 'mutant' forms of p53-Val135. J Mol Biol. 216:1990;481-484.
178. Medcalf E.A., Milner J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+p53 conformation. Oncogene. 8:1993;2847-2851.
179. Ryan J.J., Prochownik E., Gottlieb C.A. et al. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA. 91:1994;5878-5882.
180. Martinez J.D., Craven M.T., Joseloff E. et al. Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation. Oncogene. 14:1997;2511-2520.
181. Calmels S., Hainaut P., Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 57:1997;3365-3369.
182. Hainaut P., Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:1993;4469-4473.
183. Hainaut P., Hall A., Milner J. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene. 9:1994;299-303.
184. Hainaut P., Rolley N., Davies M. et al. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism. Oncogene. 10:1995;27-32.
185. Rainwater R., Parks D., Anderson M.E. et al. Role of cysteine residues in regulation of p53 function. Mol Cell Biol. 15:1995;3892-3903.
186. Srinivasan R., Maxwell S.A. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region. Oncogene. 12:1996;193-200.
187. Sun Y., Bian J., Wang Y. et al. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene. 14:1997;385-393.
188. Verhaegh G.W., Richard M.J., Hainaut P. Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol Cell Biol. 17:1997;5699-5706.
189. Cho Y., Gorina S., Jeffrey P.D. et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
190. Jayaraman L., Murphy K.G.K., Zhu C. et al. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Develop. 11:1997;559-570.
191. Coffer A.I., Knowles P.P. Divalent metal ions induce conformational change in pure, human wild-type p53 tumor suppressor protein. Biochim Biophys Acta. 1209:1994;279-285.
192. Hainaut P., Milner J. A structural role for metal ions in the 'wild-type' conformation of the tumor suppressor protein p53. Cancer Res. 53:1993;1739-1742.
193. Hupp T.R., Meek D.W., Midgley C.A. et al. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
194. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr Biol. 4:1994;865-875.
195. Lane D.P. p53 and human cancers. Br Med Bull. 50:1994;582-599.
196. Hupp T.R., Lane D.P. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem. 270:1995;18165-18174.
197. Picksley S.M., Meek D.W., Lane D.P. The conformational change of a murine temperature-sensitive p53 protein is independent of a change in phosphorylation status. Oncogene. 7:1992;1649-1651.
198. Kumar M., Spandau D.F. The effect of phosphorylation on the antigenic reactivity of p53 in cultured human keratinocytes. Biochem Biophys Res Comm. 214:1995;744-753.
199. Ehrhart J.C., Duthu A., Ullrich S. et al. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line. Oncogene. 3:1988;595-603.
200. Hainaut P., Milner J. Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J. 11:1992;3513-3520.
201. Lane D.P., Midgley C., Hupp T. Tumour suppressor genes and molecular chaperones. Philos Trans R Soc Lond B Biol Sci. 339:1993;369-372. discussion 372-363.
202. Stürzbecher H.W., Chumakov P., Welch W.J. et al. Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene. 1:1987;201-211.
203. Blagosklonny M.V., Toretsky J., Bohen S. et al. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci
204. Shkedy D., Gonen H., Bercovich B. et al. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Lett. 348:1994;126-130.
205. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:1996;2649-2654.
206. Korsmeyer S.J., Shutter J.R., Veis D.J. et al. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:1993;327-332.
207. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 7:1995;541-546.
208. Boise L.H., Gottschalk A.R., Quintáns J. et al. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol. 200:1995;107-121.
209. Hockenbery D.M. Bcl-2, a novel regulator of cell death. Bioessays. 17:1995;631-638.
210. Korsmeyer S.J., Yin X.M., Oltvai Z.N. et al. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta. 1271:1995;63-66.
211. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature. 387:1997;773-776.
212. Kim C.N., Wang X., Huang Y. et al. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 57:1997;3115-3120.
213. Renvoizé C., Roger R., Moulian N. et al. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol. 159:1997;126-134.
214. Kluck R.M., Bossy-Wetzel E., Green D.R. et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136.
215. Adachi S., Cross A.R., Babior B.M. et al. Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. J Biol Chem. 272:1997;21878-21882.
216. Furlong I.J., Ascaso R., Lopez Rivas A. et al. Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. J Cell Sci. 110:1997;653-661.
217. Schendel S.L., Xie Z., Montal M.O. et al. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA. 94:1997;5113-5118.
218. Nuñez G., London L., Hockenbery D. et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 144:1990;3602-3610.
219. Baffy G., Miyashita T., Williamson J.R. et al. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem. 268:1993;6511-6519.
220. Orth K., Dixit V.M. Bik and Bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis. J Biol Chem. 272:1997;8841-8844.
221. Wissing D., Mouritzen H., Egeblad M. et al. Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. Proc Natl Acad Sci USA. 94:1997;5073-5077.
222. Nunez G., Benedict M.A., Hu Y. et al. Caspases: the proteases of the apoptotic pathway. Oncogene. 17:1998;3237-3245.
223. Boise L.H., González-García M., Postema C.E. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
224. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
225. Zhan Q., Fan S., Bae I. et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 9:1994;3743-3751.
226. Hughes P.E., Alexi T., Yoshida T. et al. Excitotoxic lesion of rat brain with quinolinic acid induces expression of p53 messenger RNA and protein and p53-inducible genes Bax and Gadd-45 in brain areas showing DNA fragmentation. Neuroscience. 74:1996;1143-1160.
227. Han J., Sabbatini P., Perez D. et al. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 10:1996;461-477.
228. Miyashita T., Harigai M., Hanada M. et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:1994;3131-3135.
229. Klippel A., Escobedo J.A., Fantl W.J. et al. The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor. Mol Cell Biol. 12:1992;1451-1459.
230. McGlade C.J., Ellis C., Reedijk M. et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol. 12:1992;991-997.
231. Holt K.H., Olson L., Moye-Rowley W.S. et al. Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Mol Cell Biol. 14:1994;42-49.
232. Hu P., Schlessinger J. Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta. Mol Cell Biol. 14:1994;2577-2583.
233. Minshall C., Arkins S., Freund G.G. et al. Requirement for phosphatidylinositol 3′-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol. 156:1996;939-947.
234. Kennedy S.G., Wagner A.J., Conzen S.D. et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:1997;701-713.
235. Liesveld J.L., Winslow J.M., Frediani K.E. et al. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood. 81:1993;112-121.
236. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1997;1595-1606.
237. Hemmings B.A. Akt signaling: linking membrane events to life and death decisions. Science. 275:1997;628-630.
238. Franke T.F., Yang S.I., Chan T.O. et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:1995;727-736.
239. Alessi D.R., James S.R., Downes C.P. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 7:1997;261-269.
240. McGahon A.J., Nishioka W.K., Martin S.J. et al. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem. 270:1995;22625-22631.
241. Evans C.A., Lord J.M., Owen-Lynch P.J. et al. Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. J Cell Sci. 108:1995;2591-2598.
242. Cortez D., Stoica G., Pierce J.H. et al. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 13:1996;2589-2594.
243. Sánchez-García I., Grütz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA. 92:1995;5287-5291.
244. Sánchez-García I., Martín-Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol. 267:1997;225-228.
245. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E. et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-548.
246. Gomez Manzano C., Fueyo J., Kyritsis A.P. et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56:1996;694-699.
247. Gardner A.M., Johnson G.L. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J Biol Chem. 271:1996;14560-14566.
248. Kinoshita T., Shirouzu M., Kamiya A. et al. Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Oncogene. 15:1997;619-627.
249. Troppmair J., Cleveland J.L., Askew D.S. et al. v-Raf/v-Myc synergism in abrogation of Il-3 dependence: v-Raf suppresses apoptosis. Curr Top Microbiol Immunol. 182:1992;453-460.
250. Cleveland J.L., Troppmair J., Packham G. et al. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 9:1994;2217-2226.
251. Chao J.R., Chen C.S., Wang T.F. et al. Characterization of factor-independent variants derived from TF-1 hematopoietic progenitor cells: the role of the Raf/MAP kinase pathway in the anti-apoptotic effect of GM-CSF. Oncogene. 14:1997;721-728.
252. Liu L., Damen J.E., Cutler R.L. et al. Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc. Mol Cell Biol. 14:1994;6926-6935.
253. Boswell H.S. Oncogene intervention into hematopoietic signaling. J Lab Clin Med. 120:1992;681-687.
254. Evan G.I., Littlewood T.D. The role of c-myc in cell growth. Curr Opin Genet Dev. 3:1993;44-49.
255. Garte S.J. The c-myc oncogene in tumor progression. Crit Rev Oncog. 4:1993;435-449.
256. Askew D.S., Ashmun R.A., Simmons B.C. et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922.
257. Marcu K.B., Bossone S.A., Patel A.J. myc function and regulation. Annu Rev Biochem. 61:1992;809-860.
258. Bartley T.D., Bogenberger J., Hunt P. et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 77:1994;1117-1124.
259. de Sauvage F.J., Hass P.E., Spencer S.D. et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 369:1994;533-538.
260. Lok S., Kaushansky K., Holly R.D. et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 369:1994;565-568.
261. Kaushansky K., Lok S., Holly R.D. et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 369:1994;568-571.
262. Wendling F., Maraskovsky E., Debili N. et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 369:1994;571-574.
263. Kelemen E. Thrombopoietin. Br Med J. 2:1970;733-734.
264. Ichikawa N., Ishida F., Shimodaira S. et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost. 76:1996;156-160.
265. Sungaran R., Markovic B., Chong B.H. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 89:1997;101-107.
266. McDonald T.P. Role of the kidneys in thrombopoietin production. Exp Hematol. 4:1976;27-31.
267. Carver-Moore K., Broxmeyer H.E., Luoh S.M. et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood. 88:1996;803-808.
268. Goncalves F., Lacout C., Villeval J.L. et al. Thrombopoietin does not induce lineage-restricted commitment of Mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. Blood. 89:1997;3544-3553.
269. Itoh R., Katayama N., Kato T. et al. Activity of the ligand for c-mpl, thrombopoietin, in early haemopoiesis. Br J Haematol. 94:1996;228-235.
270. Rasko JE, O'Flaherty E, Begley CG. Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors. Stem Cells 1997;15:33-42.
271. Yoshida M., Tsuji K., Ebihara Y. et al. Thrombopoietin alone stimulates the early proliferation and survival of human erythroid, myeloid and multipotential progenitors in serum-free culture. Br J Haematol. 98:1997;254-264.
272. Cohen-Solal K., Debili N., Vainchenker W. et al. Thrombopoietin (Mpl-ligand) and the regulation of platelet production. Thromb Haemost. 78:1997;37-41.
273. Eaton D.L., de Sauvage F.J. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol. 25:1997;1-7.
274. Broudy V.C., Lin N.L., Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 85:1995;1719-1726.
275. Ramsfjell V., Borge O.J., Cui L. et al. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol. 158:1997;5169-5177.
276. Osada M., Komeno T., Todokoro K. et al. Immature megakaryocytes undergo apoptosis in the absence of thrombopoietin. Exp Hematol. 27:1999;131-138.
277. Matsunaga T., Kato T., Miyazaki H. et al. Thrombopoietin promotes the survival of murine hematopoietic long-term reonstituting cells: comparison with the effects of FLT3/FLK-2 ligand and interleukin-6. Blood. 92:1998;452-461.
278. Drexler H.G., Zaborski M., Quentmeier H. Thrombopoietin supports the continuous growth of cytokin-dependent human leukemia cell lines. Leukemia. 11:1997;541-551.
279. Kaushansky K., Broudy V.C., Lin N. et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA. 92:1995;3234-3238.
280. Schattner M., Lefebvre P., Mingolelli S.S. et al. Thrombopoietin-stimulated ex vivo expansion of human bone marrow megakaryocytes. Stem Cells. 14:1996;207-214.
281. Gurney A.L., Carver-Moore K., de Sauvage F.J. et al. Thrombocytopenia in c-mpl-deficient mice. Science. 265:1994;1445-1447.
282. Banu N., Wang J.F., Deng B. et al. Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand. Blood. 86:1995;1331-1338.
283. Drexler H.G., Quentmeier H. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Leukemia. 10:1996;1405-1421.
284. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 74:1995;521-525.
285. LaIuppa J.A., Papoutsakis E.T., Miller W.M. Evaluation of cytokines for expansion of the megakaryocyte and granulocyte lineages. Stem Cells. 15:1997;198-206.
286. Vigon I., Mornon J.P., Cocault L. et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA. 89:1992;5640-5644.
287. Skoda R.C., Seldin D.C., Chiang M.K. et al. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 12:1993;2645-2653.
288. Methia N., Debili N., Titeux M. et al. From the v-mpl oncogene to thrombopoietin. C R Acad Sci III. 318:1995;479-482.
289. Drachman J.G., Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA. 94:1997;2350-2355.
290. Gurney A.L., Wong S.C., Henzel W.J. et al. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA. 92:1995;5292-5296.
291. Porteu F., Rouyez M.C., Cocault L. et al. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin. Mol Cell Biol. 16:1996;2473-2482.
292. Murakami M., Narazaki M., Hibi M. et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA. 88:1991;11349-11353.
293. Morella K.K., Bruno E., Kumaki S. et al. Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells. Blood. 86:1995;557-571.
294. Oda A., Ozaki K., Druker B.J. et al. p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Blood. 88:1996;1330-1338.
295. Takatoku M., Kametaka M., Shimizu R. et al. Identification of functional domains of the human thrombopoietin receptor required for growth and differentiation of megakaryocytic cells. J Biol Chem. 272:1997;7259-7263.
296. Rui H., Lebrun J.J., Kirken R.A. et al. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology. 135:1994;1299-1306.
297. DaSilva L., Howard O.M., Rui H. et al. Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem. 269:1994;18267-18270.
298. Sakamoto K.M., Mignacca R.C., Gasson J.C. Signal transduction by granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors. Recept. Channels. 2:1994;175-181.
299. Bacon C.M., Tortolani P.J., Shimosaka A. et al. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett. 370:1995;63-68.
300. Brizzi M.F., Dentelli P., Lanfrancone L. et al. Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation. Oncogene. 13:1996;2067-2076.
301. Dorsch M., Fan P.D., Bogenberger J. et al. TPO and IL-3 induce overlapping but distinct protein tyrosine phosphorylation in a myeloid precursor cell line. Biochem Biophys Res Commun. 214:1995;424-431.
302. Drachman J.G., Sabath D.F., Fox N.E. et al. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood. 89:1997;483-492.
303. Ezumi Y., Takayama H., Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 374:1995;48-52.
304. Kaushansky K. The mpl ligand: molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells. 12(Suppl 1):1994;91-96. discussion 96-97.
305. Kojima H., Hamazaki Y., Nagata Y. et al. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost. 74:1995;1541-1545.
306. Komatsu N., Kunitama M., Yamada M. et al. Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO. Blood. 87:1996;4552-4560.
307. Morita H., Tahara T., Matsumoto A. et al. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett. 395:1996;228-234.
308. Mu S.X., Xia M., Elliott G. et al. Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells. Blood. 86:1995;4532-4543.
309. Nagata Y., Todokoro K. Thrombopoietin induces activation of at least two distinct signaling pathways. FEBS Lett. 377:1995;497-501.
310. Nagata Y., Nagahisa H., Nagasawa T. et al. Regulation of megakaryocytopoiesis by thrombopoietin and stromal cells. Leukemia. 11(Suppl 3):1997;435-438.
311. Pallard C., Gouilleux F., Bé L. et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 14:1995;2847-2856.
312. Rodríguez-Liñares B., Watson S.P. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J. 316:1996;93-98.
313. Sasaki K., Odai H., Hanazono Y. et al. TPO/c-mpl ligand induces tyrosine phosphorylation of multiple cellular proteins including proto-oncogene products, Vav and c-Cbl, and Ras signaling molecules. Biochem Biophys Res Commun. 216:1995;338-347.
314. Sattler M., Durstin M.A., Frank D.A. et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 23:1995;1040-1048.
315. Sattler M., Salgia R., Durstin M.A. et al. Thrombopoietin induces activation of the phosphatidylinositol-3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 171:1997;28-33.
316. Tortolani P.J., Johnston J.A., Bacon C.M. et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood. 85:1995;3444-3451.
317. Ihle J.N., Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11:1995;69-74.
318. Ihle J.N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol. 60:1995;1-35.
319. Drachman J.G., Griffin J.D., Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 270:1995;4979-4982.
320. Dorsch M., Fan P.D., Danial N.N. et al. The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway. J Exp Med. 186:1997;1947-1955.
321. Darnell J.E. Jr, Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421.
322. Schindler C., Darnell J.E. Jr Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 64:1995;621-651.
323. Darnell J.E. Jr STATs and gene regulation. Science. 277:1997;1630-1635.
324. Miyakawa Y., Oda A., Druker B.J. et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood. 87:1996;439-446.
325. Alexander W.S., Maurer A.B., Novak U. et al. Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J. 15:1996;6531-6540.
326. Hill R.J., Zozulya S., Lu Y.L. et al. Differentiation induced by the c-Mpl cytokine receptor is blocked by mutant Shc adaptor protein. Cell Growth Differ. 7:1996;1125-1134.
327. Pelicci G., Lanfrancone L., Grignani F. et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 70:1992;93-104.
328. Giorgetti S., Pelicci P.G., Pelicci G. et al. Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor. Eur J Biochem. 223:1994;195-202.
329. Lowenstein E.J., Daly R.J., Batzer A.G. et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70:1992;431-442.
330. Hu P., Margolis B., Schlessinger J. Vav: a potential link between tyrosine kinases and ras-like GTPases in hematopoietic cell signaling. Bioessays. 15:1993;179-183.
331. Feig L.A. The many roads that lead to Ras. Science. 260:1993;767-768.
332. Overbeck A.F., Brtva T.R., Cox A.D. et al. Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol Reprod Dev. 42:1995;468-476.
333. Bustelo X.R. The VAV family of signal transduction molecules. Crit Rev Oncog. 7:1996;65-88.
334. Yamada M., Komatsu N., Okada K. et al. Thrombopoietin induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in a human thrombopoietin-dependent cell line. Biochem Biophys Res Commun. 217:1995;230-237.
335. Rouyez M.C., Boucheron C., Gisselbrecht S. et al. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 17:1997;4991-5000.
336. Kan O., Evans C.A., Whetton A.D. Cellular signalling events stimulated by myeloid haemopoietic growth factors. Baillieres Clin Haematol. 5:1992;653-679.
337. Hirano T., Matsuda T., Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells (Dayt). 12:1994;262-277.
338. Ihle J.N., Witthuhn B.A., Quelle F.W. et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 13:1995;369-398.
339. Kahn S., Yamamoto F., Almoguera C. et al. The c-K-ras gene and human cancer (review). Anticancer Res. 7:1987;639-652.
340. Anderson M.W., Reynolds S.H., You M. et al. Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect. 98:1992;13-24.
341. Rhim J.S. Neoplastic transformation of human cells in vitro. Crit Rev Oncog. 4:1993;313-335.
342. Chambers A.F., Tuck A.B. Ras-responsive genes and tumor metastasis. Crit Rev Oncog. 4:1993;95-114.
343. Guan K.L. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal. 6:1994;581-589.
344. Seger R., Krebs E.G. The MAPK signaling cascade. Faseb J. 9:1995;726-735.
345. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol. 8:1996;205-215.
346. Su B., Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 8:1996;402-411.
347. Miyazawa K., Hendrie P.C., Mantel C. et al. Comparative analysis of signaling pathways between mast cell growth factor (c-kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factor-dependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating protein and mitogen-activated protein kinase. Exp Hematol. 19:1991;1110-1123.
348. Welham M.J., Duronio V., Sanghera J.S. et al. Multiple hemopoietic growth factors stimulate activation of mitogen-activated protein kinase family members. J Immunol. 149:1992;1683-1693.
349. Ferrell J.E. Jr, Bhatt R.R. Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase. J Biol Chem. 272:1997;19008-19016.
350. Ward Y., Gupta S., Jensen P. et al. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature. 367:1994;651-654.
351. Gardner A.M., Vaillancourt R.R., Johnson G.L. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 268:1993;17896-17901.
352. Burack W.R., Sturgill T.W. The activating dual phosphorylation of MAPK by MEK is nonprocessive. Biochemistry. 36:1997;5929-5933.
353. Rao V.N., Reddy E.S. elk-1 proteins interact with Map kinases. Oncogene. 9:1994;1855-1860.
354. Hsiao K.M., Chou S.Y., Shih S.J. et al. Evidence that inactive p42 mitogen-activated protein kinase and inactive Rsk exist as a heterodimer in vivo. Proc Natl Acad Sci USA. 91:1994;5480-5484.
355. Xing J., Ginty D.D., Greenberg M.E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 273:1996;959-963.
356. Chauhan D., Kharbanda S.M., Uchiyama H. et al. Activation of pp90rsk and early growth response-1 gene expression by pokeweed mitogen in human B cells. Leuk Res. 19:1995;337-344.
357. Gille H., Kortenjann M., Strahl T. et al. Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Mol Cell Biol. 16:1996;1094-1102.
358. Xia Z., Dickens M., Raingeaud J. et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
359. Goruppi S., Ruaro E., Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene. 12:1996;471-480.
360. Sakakura C., Igarashi Y., Anand J.K. et al. Plasmalopsychosine of human brain mimics the effect of nerve growth factor by activating its receptor kinase and mitogen-activated protein kinase in PC12 cells. Induction of neurite outgrowth and prevention of apoptosis. J Biol Chem. 271:1996;946-952.
361. Wilson D.J., Fortner K.A., Lynch D.H. et al. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Eur J Immunol. 26:1996;989-994.
362. Whalen A.M., Galasinski S.C., Shapiro P.S. et al. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol. 17:1997;1947-1958.
363. Chen J., Herceg-Harjacek L., Groopman J.E. et al. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood. 86:1995;4054-4062.
364. Cui L., Ramsfjell V., Borge O.J. et al. Thrombopoietin promotes adhesion of primitive human hemopoietic cells to fibronectin and vascular cell adhesion molecule - 1: role of activation of very late antigen (VLA)-4 and VLA-5. J Immunol. 159:1997;1961-1969.
365. Kodaki T., Woscholski R., Hallberg B. et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol. 4:1994;798-806.
366. Nagata Y., Nishida E., Todokoro K. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood. 89:1997;2664-2669.
367. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem Sci. 19:1994;470-473.
368. Cano E., Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci. 20:1995;117-122.
369. Holbrook N.J., Liu Y., Fornace A.J. Jr Signaling events controlling the molecular response to genotoxic stress. Exs. 77:1996;273-288.
370. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci. 351:1996;127-134.
371. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 9:1997;240-246.
372. Avanzi G.C., Lista P., Giovinazzo B. et al. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 69:1988;359-366.
373. Hendrie P.C., Miyazawa K., Yang Y.C. et al. Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp Hematol. 19:1991;1031-1037.
374. Traycoff C.M., Kosak S.T., Grigsby S. et al. Evaluation of ex vivo expansion potential of cord blood and bone marrow hematopoietic progenitor cells using cell tracking and limiting dilution analysis. Blood. 85:1995;2059-2068.
375. Orazi A., Kahsai M., John K. et al. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. Mod Pathol. 9:1996;48-52.
376. Russell N.H., Hunter A.E., Bradbury D. et al. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma. 16:1995;223-229.
377. Zhu Y.M., Bradbury D., Russell N. Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer. 68:1993;851-855.